"In keeping with our growth plans, we would look for opportunities in our chosen areas of business, which includes branded products in the US," Kamal K Sharma managing director, Lupin Ltd said.
"Paediatric segment is $7.8 billion in value and is a niche area. It also fits well with our delivery research objective," he said, adding Lupin had set up a dedicated sales force to focus on the paediatric segment in the US market.
Sharma said the company was also working on developing new products from its research initiative to augment its offerings in this niche market where not many companies had a dedicated focus.
He, however, declined to give any timeframe or possible targets for acquisition and buying of brands.
"It is not possible to say anything more specific now," he said. Asked about the funding of the acquisition, Sharma did not rule out utilising funds to be raised through its proposed selling of convertible bonds worth $100 million overseas.
"The proceeds, if and when issued, will be used for financing the growth of the company. That means the funds can be used for internal capital expenditure and/or for inorganic acquisitions," he said.
© 2025